A lagille syndrome is an autosomal-dominant genetic disease mapped to 20p12.1 (1) and caused by defects in the Notch signaling pathway, which can affect the liver, heart, skeleton, eyes, kidney, and central nervous system. It is estimated to have a prevalence of 1 in 70,000 to 100,000 live births (2) . The clinical diagnosis can be made if 3 or more of the following major features are present: cardiac murmur, posterior embryotoxon, butterflylike vertebrae, renal abnormalities, and characteristic facies in the presence of bile duct paucity (3, 4) .
The majority of cases (~97%) are caused by haploinsufficiency of the JAG1 gene (1, 5) on 20p11.2-20p12 (encoding Jagged-1), either because of mutations (the majority) or deletions at the locus. A small percentage (,1%) are caused by mutations in NOTCH2 (6), in which group renal malformations may be more common. New mutations occur commonly (~60%), and the rate of germline mosaicism may also be relatively high. Both genes are components of the Notch signaling pathway (3).
Case Report
We report the case of a male patient who was born as a full-term infant with no complications during gestation or delivery. He was a product of healthy nonconsanguineous parents with no notable medical history. At 1 month of age, he was diagnosed with pulmonary valve stenosis. During his first year of life, he presented with failure to thrive, jaundice, intermittent pruritus, and multiple skin nodules with the appearance of xanthomas that had grown in size and number over time. Pertinent findings on physical examination included a thin infant with pallor; short stature for stated age; icteric conjunctiva; triangular face; frontal bossing; broad forehead; 2/6 systolic murmur at the second left supraclavicular space; barrel chest; hepatomegaly; and multiple symmetrical, yellowish, firm papules and nodules on extensor and flexor areas including the hands, fingers, toes, ankles, elbows, knees, buttocks, groin, neck, underarms, and eyelids (excluding the palms and soles) ( Figs. 1 and 2 Because of the very high cholesterol level, the patient was referred to a lipidologist who, because of the severity of hypercholesterolemia and the presence of multiple skin xanthomas in an infant, entertained the diagnosis of homozygous familial hypercholesterolemia. The absence of hypercholesterolemia in the child's parents, which is obligatory in homozygous familial hypercholesterolemia, and the relatively low apo B value, which should be .300 mg/dL in severe familial hypercholesterolemia (7), excluded that diagnosis. Later, the clinical diagnosis of Alagille syndrome was suspected, and it was then recognized that the more likely diagnosis was very severe hypercholesterolemia associated with cholestasis in Alagille syndrome.
The diagnosis of Alagille syndrome was confirmed by genetic testing, which identified a heterozygous variant in the JAG1 gene, p.Arg486Lysfs*5. This variant had not been previously reported in the Human Gene Mutation Database and Exome Aggregation Consortium database. This is a frameshift mutation predicted to result in premature truncation of the protein product encoded by this gene, considered to be pathogenic. The patient was started on treatment with Ursodiol ® , which he has been tolerating very well, with improvement of pruritus and skin icteric findings. A multidisciplinary medical team that provides support to the patient and his family has closely followed the patient; the team includes a pediatrician, cardiologist, gastroenterologist, geneticist, ophthalmologist, and endocrinologist. press.endocrine.org/journal/jcemreceptors. These are transmembrane proteins, and interactions with their ligands trigger a cascade of intracellular downstream effects that result in transcription of genes that help determine cell fate and differentiation (3). The spectrum of JAG1 mutations associated with Alagille syndrome includes full gene deletions and other protein-truncating mutations including nonsense, frameshift, and splice site as well as missense mutations, suggesting that the clinical phenotype is caused by haploinsufficiency for JAG1 (8, 9) . Phenotypic effects of JAG1 mutations are highly penetrant but with variable expressivity (10) . There is a high rate of de novo mutations, with~60% of mutations in probands not found in either parent. There is no strong correlation between the type and location of the JAG1 mutation and the severity of the disease, suggesting that other genomic modifiers beyond the known JAG1 mutation may be the cause of the variable expressivity that characterizes this disorder (8) .
Because of the possibility of germline mosaicism in either parent, the risk of recurrence in further offspring, though low, is greater than that in the general population. The offspring of patients with Alagille syndrome have a 50% chance of inheriting the disease.
Alagille syndrome is associated with intrahepatic bile duct paucity; liver biopsy is not considered mandatory to establish the diagnosis. In addition to abnormal liver function test results, most patients with Alagille syndrome have increased serum total cholesterol, triglyceride, phospholipid, and low-density lipoprotein cholesterol (LDL-C) concentrations (11) . The hypercholesterolemia seen is due to cholestasis.
The plasma lipoprotein profiles in Alagille syndrome have been documented in many earlier reports (12) (13) (14) . A previous cross-sectional study of the lipoprotein pattern of patients with Alagille syndrome divided subjects into 2 groups according to severity and reported mean total cholesterol and triglyceride levels of 720 and 97 mg/dL, respectively, in the more severe case group (12) . The patient presented in this case report had levels much higher than those previously reported in the literature.
The increase in serum cholesterol and LDL-C concentrations associated with cholestatic liver disease is caused by multiple abnormalities in cholesterol regulation. These include (1) development of an abnormal lipoprotein formed as a complex of free cholesterol and albumin that is typical of chronic cholestasis and cannot be effectively cleared, (2) increased cholesterol production in cholestasis, and (3) other abnormalities in hepatic cholesterol regulation seen in Alagille syndrome that may be different from other causes of cholestasis. shown that severe cholestasis induces 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG CoA reductase) expression in the liver, thus contributing to hypercholesterolemia (15) . The expression and activity of liver cholesterol regulators may differ with the severity of cholestasis. 3. HMG CoA reductase and LDL receptor expression are regulated by the sterol regulatory elementbinding protein-2 transcription factor (16). Sterol regulatory element-binding protein-2 messenger RNA is transcriptionally suppressed by liver X receptor a. Alagille syndrome patients have been found to have significantly elevated levels of liver X receptor a messenger RNA. Also, the liver expression of CYP7A1, a rate-limiting enzyme of bile acid synthesis, was found to be decreased in these patients, indicating that a decrease in the conversion from cholesterol to bile acid contributed, at least in part, to the high cholesterol content in the liver of Alagille syndrome patients. Prior studies have shown that the major upregulators of liver cholesterol may be increased in Alagille syndrome patients, indicating an impaired negative feedback mechanism and accelerated liver cholesterol accumulation (12) .
Whether the hypercholesterolemia seen in these cases leads to atherosclerosis is argued (17, 18) . Some cases of atheromatous vascular disease in Alagille syndrome have been published (19, 20) . On the basis of data in adults with chronic cholestasis, it has been suggested that LpX is not atherogenic. Cholestyramine treatment does not seem to cause evident changes in lipid pattern (11, 13, 18) , and the only way to lower the cholesterol level is through plasmapheresis or liver transplant, which is indicated only when the condition is considered life threatening.
Patients with Alagille syndrome should be managed by a multidisciplinary medical team to provide monitoring and support of the multiple systems affected. Close follow-up of growth, development, nutritional status, liver function tests, and cardiac function is needed. Pruritus can be successfully treated with choleretic agents such as ursodeoxycholic acid and cholestyramine, rifampin, or naltrexone. Biliary diversion may be helpful before liver transplantation. The success of liver transplantation is often related to coexisting cardiac and renal impairment (21) . It is not clear if patients with Alagille syndrome have a higher incidence of mental retardation than the general population because studies that have suggested this may represent ascertainment bias. With aggressive treatment, these patients might show no difference in learning difficulties than the general population, although there seems to be a higher frequency of motor delay. Learning difficulties seem to be more common in cases with large cytogenetic deletions (3).
Conclusions
Alagille syndrome is a rare genetic disorder that involves multiple organ systems. Bile duct paucity is the main characteristic feature of the disease, which often leads to cholestatic hypercholesterolemia. The degree of hyperbilirubinemia and hypercholesterolemia has been shown to be associated with the severity of liver disease and might be a useful predictor tool to use as a management guideline (22) . Here, we report a unique case of a patient diagnosed with Alagille syndrome and found to have a previously undescribed frameshift pathogenic mutation in the JAG1 gene, presenting with levels of hypercholesterolemia more than 2 times higher than the levels previously reported in the literature (13, 18, 22) as well as the unusual finding of very severe diffuse symmetrical skin xanthomas.
